Ventilator Acquired Pneumonia in COVID-19 ICU Patients : A Retrospective Cohort Study during Pandemia in France

Describe the characteristics of ventilation-acquired pneumonia (VAP) and potential risk factors in critically ill SARS-CoV-2 patients admitted in three French public hospitals during the first year of the COVID-19 pandemic. We conducted a monocentric retrospective study in seven Marseille intensive care units (ICUs) aiming to describe VAP characteristics and identify their risk factors. VAP patients were compared to a non-VAP control group. From March to November 2020, 161 patients admitted for viral-induced acute respiratory failure (ARF) requiring invasive mechanical ventilation (IMV) were included. This cohort was categorized in two groups according to the development or not of a VAP during their stay in ICU. 82 patients (51%) developed ventilation-acquired pneumonia. Most of them were men (77%) and 55% had hypertension. In the VAP population, 31 out of 82 patients (38%) had received dexamethasone and 47% were administered antibiotic course prior to ICU admission. An amount of 88% of respiratory infections were late VAPs with a median delay of 10 days from the onset of IMV. Gram negative bacteria were responsible for 62% of VAPs with Pseudomonas spp. being the most documented bacteria. Less than a third of the ICU-acquired infections were due to multidrug resistant (MDR) bacteria mainly displaying AmpC cephalosporin hyper production resistance phenotype. Multivariate analysis revealed that early Dexamethasone administration in ICU, male sex, older age and ROX score were risk factors for VAP whereas pre-ICU antimicrobial treatment and higher IGS 2 were protective factors. VAP is a frequent ICU-related complication affecting half of patients infected with SARS-CoV-2 and requiring IMV. It was responsible for increased morbidity due to a longer ICU and hospital stay. VAP risk factors included demographic factors such as age and sex. Dexamethasone was associated with a threefold greater risk of developing VAP during ICU stay. These results need to be comforted by large multi-centric studies before questioning the only available and effective treatment against SARS-CoV-2 in ICU patients.

Medienart:	E-Artikel

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	Zur Gesamtaufnahme - volume:12
Enthalten in:	Journal of clinical medicine - 12(2023), 2 vom: 04. Jan.

Sprache:	Englisch

Beteiligte Personen:	Moreno, Jacques [VerfasserIn] Carvelli, Julien [VerfasserIn] Lesaux, Audrey [VerfasserIn] Boucekine, Mohamed [VerfasserIn] Tonon, David [VerfasserIn] Bichon, Amandine [VerfasserIn] Gainnier, Marc [VerfasserIn] Bourenne, Jeremy [VerfasserIn]

Links:	Volltext

Themen:	Acute respiratory failure Early antibio-therapy Infectious risk factors Journal Article SARS-CoV-2 pneumonia Ventilor acquired pneumonia

Anmerkungen:	Date Revised 28.03.2023 published: Electronic Citation Status PubMed-not-MEDLINE

doi:	10.3390/jcm12020421

funding:
Förderinstitution / Projekttitel:

PPN (Katalog-ID):	NLM351860703